339P - Fulvestrant 500 Mg as First-Line Treatment in Hormone-Positive (HR+) Metastatic Breast Cancer (MBC) Patients (PTS): Prospective Evaluation of Activity, Safety, Quality of Life (QOL) and Tumour Markers Changes
| Autor: | Palumbo, R., Bernardo, G., Riccardi, A., Sottotetti, F., Tagliaferri, B., Pozzi, E., Teragni, C.M., Bernardo, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2012 23 Supplement 9:ix123-ix123 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|